BACKGROUND: Noneosinophilic asthma is common across asthma severities. However, in patients with moderate-to-severe disease, the absence of sputum eosinophilia cannot distinguish between asthmatic subjects with eosinophilic inflammation controlled by corticosteroids versus those in whom eosinophilic inflammation is not a component of the disease. OBJECTIVES: We sought to develop a method to quantify eosinophil proteins in airway macrophages as a novel biomarker of eosinophilic airway inflammation. METHODS: Eosinophil proteins in airway macrophages were assessed by means of flow cytometry, immunofluorescence, and cytoplasmic hue change after ingestion of apoptotic eosinophils. Airway macrophage median percentage of red-hued area in stained sputum cytospin preparations was assessed by means of image analysis from (1) subjects with mild-to-severe asthma, subjects with nonasthmatic eosinophilic bronchitis, and healthy control subjects; (2) subjects with eosinophilic severe asthma after treatment with prednisolone; and (3) subject with noneosinophilic asthma before corticosteroid withdrawal. RESULTS: Eosinophil proteins were detected in airway macrophages, and cytoplasmic red hue increased after ingestion of apoptotic eosinophils. Airway macrophage percentage redhued area was increased in subjects with moderate-to-severe asthma compared with that seen in subjects with mild asthma and healthy control subjects, was similar in those with or without a sputum eosinophilia, and was increased after corticosteroid therapy. In asthmatic subjects without sputum eosinophilia, the airway macrophage percentage red-hued area was increased in subjects who did versus those who did not have sputum eosinophilia after corticosteroid withdrawal. CONCLUSIONS: Eosinophil proteins can be reliably measured in airway macrophages. In combination with sputum eosinophilia, the macrophage eosinophil protein content might further define the asthma phenotype and provide an additional tool to direct therapy.
BACKGROUND:Noneosinophilic asthma is common across asthma severities. However, in patients with moderate-to-severe disease, the absence of sputum eosinophilia cannot distinguish between asthmatic subjects with eosinophilic inflammation controlled by corticosteroids versus those in whom eosinophilic inflammation is not a component of the disease. OBJECTIVES: We sought to develop a method to quantify eosinophil proteins in airway macrophages as a novel biomarker of eosinophilic airway inflammation. METHODS: Eosinophil proteins in airway macrophages were assessed by means of flow cytometry, immunofluorescence, and cytoplasmic hue change after ingestion of apoptotic eosinophils. Airway macrophage median percentage of red-hued area in stained sputum cytospin preparations was assessed by means of image analysis from (1) subjects with mild-to-severe asthma, subjects with nonasthmatic eosinophilic bronchitis, and healthy control subjects; (2) subjects with eosinophilic severe asthma after treatment with prednisolone; and (3) subject with noneosinophilic asthma before corticosteroid withdrawal. RESULTS: Eosinophil proteins were detected in airway macrophages, and cytoplasmic red hue increased after ingestion of apoptotic eosinophils. Airway macrophage percentage redhued area was increased in subjects with moderate-to-severe asthma compared with that seen in subjects with mild asthma and healthy control subjects, was similar in those with or without a sputum eosinophilia, and was increased after corticosteroid therapy. In asthmatic subjects without sputum eosinophilia, the airway macrophage percentage red-hued area was increased in subjects who did versus those who did not have sputum eosinophilia after corticosteroid withdrawal. CONCLUSIONS: Eosinophil proteins can be reliably measured in airway macrophages. In combination with sputum eosinophilia, the macrophage eosinophil protein content might further define the asthma phenotype and provide an additional tool to direct therapy.
Authors: J C in't Veen; H H Smits; P S Hiemstra; A E Zwinderman; P J Sterk; E H Bel Journal: Am J Respir Crit Care Med Date: 1999-07 Impact factor: 21.405
Authors: L Jayaram; M M Pizzichini; R J Cook; L-P Boulet; C Lemière; E Pizzichini; A Cartier; P Hussack; C H Goldsmith; M Laviolette; K Parameswaran; F E Hargreave Journal: Eur Respir J Date: 2006-03 Impact factor: 16.671
Authors: Christiane Lex; Gavin Jenkins; Nicola M Wilson; Angela Zacharasiewicz; Ed Erin; Trevor T Hansel; Andrew Bush; Donald N R Payne Journal: Pediatr Pulmonol Date: 2007-03
Authors: Mike A Berry; Deborah Parker; Natalie Neale; Lucy Woodman; Angela Morgan; Phillip Monk; Peter Bradding; Andrew J Wardlaw; Ian D Pavord; Christopher E Brightling Journal: J Allergy Clin Immunol Date: 2004-11 Impact factor: 10.793
Authors: Catherine Lemière; Caroline Tremblay; Mark FitzGerald; Shawn D Aaron; Richard Leigh; Louis-Philippe Boulet; James G Martin; Parameswaran Nair; Ronald Olivenstein; Simone Chaboillez Journal: Can Respir J Date: 2011 Sep-Oct Impact factor: 2.409
Authors: Hongjun Jin; Teal S Hallstrand; Don S Daly; Melissa M Matzke; Parameswaran Nair; Diana J Bigelow; Joel G Pounds; Richard C Zangar Journal: J Immunol Methods Date: 2013-12-02 Impact factor: 2.303
Authors: David M Pyle; Victoria S Yang; Rebecca S Gruchalla; J David Farrar; Michelle A Gill Journal: J Allergy Clin Immunol Date: 2013-02 Impact factor: 10.793